NCT04078152: Durvalumab Long-Term Safety and Efficacy Study

NCT04078152
Breast Cancer Type: HER2+, HR+ & HER2-negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 4
Drug Category: Therapeutic Antibody, Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 130 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient received durvalumab monotherapy and/or durvalumab containing combination in an AstraZeneca/MedImmune-sponsored parent clinical study that is approved for enrollment into this study
Exclusions: Patients receiving any concurrent chemotherapy, biologic or hormonal therapy for cancer treatment
https://ClinicalTrials.gov/show/NCT04078152

Comments are closed.

Up ↑